StockNews.AI

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

StockNews.AI • 23 hours

RGENAMGNVRTX
High Materiality9/10

Information

Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 ...

Original source

AI Summary

C4 Therapeutics to initiate Phase 2 MOMENTUM trial in Q1 2026. Cemsidomide shows promising results in myeloma treatments. Cash runway extended to 2028 supports strategic initiatives. New discovery strategy addresses unmet needs in inflammation and neuro-degenerative diseases. Expected FDA accelerated approvals bolster C4T's market position.

Sentiment Rationale

C4T's advancements with cemsidomide and a solid pipeline may attract investor interest, evident in past uplifts from successful trial announcements.

Trading Thesis

Successful trial outcomes and subsequent FDA approvals could significantly enhance long-term growth, similar to trajectories of competitors after major drug launches.

Market-Moving

  • C4 Therapeutics to initiate Phase 2 MOMENTUM trial in Q1 2026.
  • Cemsidomide shows promising results in myeloma treatments.
  • Cash runway extended to 2028 supports strategic initiatives.

Key Facts

  • C4 Therapeutics to initiate Phase 2 MOMENTUM trial in Q1 2026.
  • Cemsidomide shows promising results in myeloma treatments.
  • Cash runway extended to 2028 supports strategic initiatives.
  • New discovery strategy addresses unmet needs in inflammation and neuro-degenerative diseases.
  • Expected FDA accelerated approvals bolster C4T's market position.

Companies Mentioned

  • RGEN (RGEN)
  • AMGN (AMGN)
  • VRTX (VRTX)

Corporate Developments

The announcement of upcoming clinical trials and a robust cash runway is pivotal for CCCC's growth potential, underscoring confidence in the company's strategic direction.

C4 Therapeutics Outlines Strategic Milestones for Cemsidomide Advancement

WATERTOWN, Mass., January 14, 2026 – C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical company specializing in targeted protein degradation, has announced a strategic plan to advance its investigational drug, cemsidomide, as a leading treatment for multiple myeloma. The company unveils plans for crucial clinical trials and an innovative discovery strategy focusing on novel therapeutic targets through 2028.

Phase 2 MOMENTUM Trial Set to Launch

C4 Therapeutics is preparing to initiate the Phase 2 MOMENTUM trial of cemsidomide, expecting to start in Q1 2026. This trial aims to ascertain the efficacy of cemsidomide in combination with dexamethasone for patients with relapsed or refractory multiple myeloma at later lines of therapy. The recommended Phase 2 dose has been established at 100 µg following discussions with the FDA.

CEO Andrew Hirsch commented, “As we prepare to initiate two cemsidomide trials in the coming months, we believe the emerging data exploring the class in combination with BiTE therapies derisks our strategy to rapidly advance cemsidomide through registrational development.”

Significant Milestones in Clinical Trials

C4 Therapeutics has laid out ongoing milestones concerning the trial of cemsidomide. Key points include:

  • Q1 2026: Begin Phase 2 MOMENTUM trial and complete enrollment within 12 months.
  • Mid-2026: Present analysis from the ongoing Phase 1 trial.
  • 2H 2027: Release initial overall response rate (ORR) data for the MOMENTUM trial.
  • Mid-2028: Share efficacy and safety data for the completion of the MOMENTUM trial.
  • Year-end 2028: Submit a new drug application for accelerated approval.

Broader Discovery Strategy Addresses Unmet Medical Needs

Alongside its clinical efforts, C4 Therapeutics is advancing a discovery strategy focused on inflammation, neuro-inflammation, and neuro-degenerative diseases. This strategy seeks to develop novel degraders targeting clinically validated pathways. The company anticipates delivering up to three investigational new drug applications by year-end 2028.

Hirsch further stated, “Our strong balance sheet provides cash runway through key inflection points, positioning us to advance our portfolio and create transformative medicines for patients.”

Impressive Achievements in 2025

In 2025, C4 Therapeutics made substantial progress, including:

  • Completion of enrollment in the Phase 1 trial, showcasing a 40% overall response rate (ORR) at 75 µg and 53% ORR at 100 µg in a heavily pretreated patient population.
  • Establishing a regulatory framework incorporating FDA feedback, allowing for potential accelerated approvals.
  • Advancing CFT8919's Phase 1 trial in China, aligning with regulatory steps for further development.

About Cemsidomide and Its Clinical Trials

Cemsidomide is an investigational, orally bioavailable molecular glue degrader targeting IKZF1/3, critical transcription factors in multiple myeloma. The Phase 2 MOMENTUM trial aims to evaluate its safety, efficacy, and pharmacokinetic properties alongside dexamethasone.

Patients selected for this trial must have undergone three prior anti-myeloma treatments, which include an IKZF1/3 degrader. Further details can be found at clinicaltrials.gov.

Future Directions and Anticipated Trials with Elranatamab

C4 Therapeutics is also set to initiate a Phase 1b trial in Q2 2026, exploring the combination of cemsidomide with elranatamab, an FDA-approved bispecific antibody. This trial seeks to establish safety and evaluate the combined treatment's efficacy in patients with a history of prior therapies.

Related News